CIRRH
MCID: LVR012
MIFTS: 67

Liver Cirrhosis (CIRRH)

Categories: Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Liver Cirrhosis

MalaCards integrated aliases for Liver Cirrhosis:

Name: Liver Cirrhosis 39 12 77 30 56 6 45 15 74
Cirrhosis 12 76 56 44 15 41 74
Cirrhosis of Liver 12 17
Cirrhosis, Cryptogenic 74
Cryptogenic Cirrhosis 76
Cirrh 76

Classifications:



Summaries for Liver Cirrhosis

MedlinePlus : 44 Cirrhosis is scarring of the liver. Scar tissue forms because of injury or long-term disease. Scar tissue cannot do what healthy liver tissue does - make protein, help fight infections, clean the blood, help digest food and store energy. Cirrhosis can lead to Easy bruising or bleeding, or nosebleeds Swelling of the abdomen or legs Extra sensitivity to medicines High blood pressure in the vein entering the liver Enlarged veins called varices in the esophagus and stomach. Varices can bleed suddenly. Kidney failure Jaundice Severe itching Gallstones A small number of people with cirrhosis get liver cancer. Your doctor will diagnose cirrhosis with blood tests, imaging tests, or a biopsy. Cirrhosis has many causes. In the United States, the most common causes are chronic alcoholism and hepatitis. Nothing will make the scar tissue disappear, but treating the cause can keep it from getting worse. If too much scar tissue forms, you may need to consider a liver transplant. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Liver Cirrhosis, also known as cirrhosis, is related to alcoholic liver cirrhosis and portal hypertension, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Liver Cirrhosis is KRT8 (Keratin 8), and among its related pathways/superpathways are Lung fibrosis and Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Adefovir Dipivoxil and Telbivudine have been mentioned in the context of this disorder. Affiliated tissues include Bone and Blood, and related phenotype is liver/biliary system.

Wikipedia : 77 Cirrhosis is a condition in which the liver does not function properly due to long-term damage. This... more...

Related Diseases for Liver Cirrhosis

Diseases related to Liver Cirrhosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 947)
# Related Disease Score Top Affiliating Genes
1 alcoholic liver cirrhosis 34.6 AFP ALB F2 SLC17A5
2 portal hypertension 31.8 ALB EDN1 F2 GPT
3 hepatitis b 31.8 AFP ALB F2 GPT SLC17A5
4 cryptogenic cirrhosis 31.8 F2 HFE KRT18 KRT8
5 hepatic encephalopathy 31.7 ALB F2 GPT SLC17A5
6 hepatic coma 31.7 ALB F2 GPT
7 esophageal varix 31.7 AFP ALB F2 SERPINC1
8 hepatoportal sclerosis 31.7 F2 GPT
9 portal vein thrombosis 31.7 AFP F2 SERPINC1
10 hepatitis 31.5 AFP F2 GPT KRT18 KRT8 SLC17A5
11 hypersplenism 31.4 ALB F2 SERPINC1
12 infantile liver failure syndrome 1 31.2 ALB F2 GPT SLC17A5
13 hepatorenal syndrome 31.2 ALB EDN1 F2 REN
14 arteries, anomalies of 31.0 ALB EDN1 REN SERPINC1
15 endocarditis 30.9 ALB F2 SERPINC1
16 cholangitis 30.9 ALB F2 GPT
17 alpha-1-antitrypsin deficiency 30.8 ALB HFE SERPINA1 SERPINC1
18 autoimmune hepatitis 30.7 F2 GPT KRT8
19 acute liver failure 30.7 ALB F2 GPT HGF SLC17A5
20 choledocholithiasis 30.7 ALB F2 GPT SLC17A5
21 hepatitis e 30.6 ALB F2 GPT
22 abdominal tuberculosis 30.5 ALB F2
23 biliary atresia 30.5 ALB GPT HGF
24 obstructive jaundice 30.5 ALB EDN1 F2 GPT HGF REN
25 diabetes mellitus, noninsulin-dependent 30.5 ALB EDN1 GAS5 GPT SLC17A5
26 antipyrine metabolism 30.5 ALB F2
27 constrictive pericarditis 30.4 ALB SERPINA1
28 viral hepatitis 30.4 AFP ALB F2 GPT HFE KRT18
29 dysfibrinogenemia 30.4 ALB F2 SERPINC1
30 homocysteinemia 30.3 ALB F2 SERPINC1
31 kwashiorkor 30.3 ALB F2 GPT SLC17A5
32 analbuminemia 30.3 ALB F2 GPT SLC17A5
33 bilirubin metabolic disorder 30.3 ALB F2 GPT SLC17A5
34 pulmonary embolism 30.3 ALB F2 SERPINC1
35 nonalcoholic steatohepatitis 30.3 F2 GPT HFE KRT18 SLC17A5
36 wilson disease 30.3 ALB F2 GPT HFE
37 compartment syndrome 30.3 ALB F2 SLC17A5
38 fascioliasis 30.3 ALB GPT SLC17A5
39 vascular disease 30.3 ALB EDN1 F2 REN SERPINC1
40 diabetes mellitus 30.3 ALB EDN1 HFE MALAT1 MEG3 REN
41 myocardial infarction 30.2 ALB EDN1 F2 REN SERPINC1
42 congenital hepatic fibrosis 30.2 REN SLC17A5
43 hepatitis a 30.1 AFP ALB F2 GPT SERPINA1
44 alcoholic hepatitis 30.1 ALB F2 GPT KRT18 SLC17A5
45 liver disease 30.1 AFP ALB F2 GPT HFE HGF
46 burns 30.1 ALB HGF SERPINC1
47 pyridoxine deficiency 30.0 GPT SLC17A5
48 renal hypertension 30.0 ALB EDN1 REN
49 obstructive nephropathy 30.0 ALB HGF REN
50 peripheral vascular disease 30.0 ALB F2 SERPINC1

Graphical network of the top 20 diseases related to Liver Cirrhosis:



Diseases related to Liver Cirrhosis

Symptoms & Phenotypes for Liver Cirrhosis

UMLS symptoms related to Liver Cirrhosis:


nausea and vomiting, constipation, abdominal pain, diarrhea, hepatosplenomegaly, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Liver Cirrhosis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.17 AFP ALB HFE HGF KRT18 KRT8

Drugs & Therapeutics for Liver Cirrhosis

Drugs for Liver Cirrhosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 774)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 142340-99-6 60871
2
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 3424-98-4 159269
3
Losartan Approved Phase 4,Phase 3 114798-26-4 3961
4
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
5
Magnesium oxide Approved Phase 4 1309-48-4 14792
6
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
7
Vancomycin Approved Phase 4,Phase 3 1404-90-6 441141 14969
8
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Early Phase 1,Not Applicable 85721-33-1 2764
9
Azithromycin Approved Phase 4 83905-01-5 55185 447043
10
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
11
Imipenem Approved Phase 4,Not Applicable 74431-23-5, 64221-86-9 104838
12
Cefoxitin Approved Phase 4 35607-66-0 441199
13
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
14
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80621-81-4 6436173 46783403
15
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 143491-57-0 60877
16
Metformin Approved Phase 4,Phase 2,Phase 3,Not Applicable 657-24-9 14219 4091
17
Simvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 79902-63-9 54454
18
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
19
Entecavir Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 142217-69-4 153941
20
Spironolactone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-01-7, 1952-01-7 5833
21
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 525-66-6 4946
22
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 72956-09-3 2585
23
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
24
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6 32051
25
Insulin glulisine Approved Phase 4 207748-29-6
26
Insulin glargine Approved Phase 4 160337-95-1
27
Lactulose Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 4618-18-2 11333
28
acetic acid Approved Phase 4 64-19-7 176
29
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
30
Nadroparin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable
31
Warfarin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81-81-2 6691 54678486
32
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1401-55-4
33
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 2078-54-8 4943
34
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
35
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Not Applicable 59467-70-8 4192
36
Tolvaptan Approved Phase 4,Phase 2,Phase 3,Phase 1 150683-30-0 216237
37
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 198153-51-4 5360545
38
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 36791-04-5 37542
39
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
40
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1 10102-43-9 145068
41
Prazosin Approved Phase 4,Phase 2 19216-56-9 4893
42
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
43
Terlipressin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 14636-12-5 72081
44
Gabapentin Approved, Investigational Phase 4,Phase 3 60142-96-3 3446
45
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
46 Ethiodized oil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 8008-53-5
47
Carboplatin Approved Phase 4,Phase 2,Phase 3 41575-94-4 38904 10339178 498142
48
Sorafenib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 284461-73-0 216239 406563
49
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1406-66-2 14986
50
Bisacodyl Approved Phase 4 603-50-9

Interventional clinical trials:

(show top 50) (show all 2041)
# Name Status NCT ID Phase Drugs
1 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
2 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4 telbivudine
3 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
4 Prevention of Decompensation in Liver Cirrhosis Unknown status NCT00239096 Phase 4 losartan (drug)
5 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
6 Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
7 Rifaximin Predicts the Complications of Decompensated Cirrhosis Unknown status NCT02074280 Phase 4 rifaximin
8 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
9 Metformin Experience on Minimal Hepatic Encephalopathy Unknown status NCT02470546 Phase 4 Metformin;Placebo
10 Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis Unknown status NCT01282398 Phase 4 Simvastatin;placebo
11 A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4 Entacavir;Tenofovir
12 Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis Unknown status NCT01693679 Phase 4 Telbivudine, Lamivudine, Adefovir ,Enecavir
13 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4 Entecavir
14 Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis Unknown status NCT00332904 Phase 4 propranolol;spironolactone
15 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease Unknown status NCT02837302 Phase 4 Livact
16 Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
17 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
18 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
19 The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding Unknown status NCT02385422 Phase 4 Carvedilol;Propranolol
20 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
21 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
22 The Effect of Hepatic Vein Pressure Gradient(HVPG)-Guided Therapy in Cirrhotic Patients With Esophagogastric Varices Unknown status NCT02638415 Phase 4 Carvedilol
23 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4 propranolol
24 The Effect of Carvedilol VS Endoscopic Therapy in Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding Unknown status NCT02695732 Phase 4 Carvedilol
25 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
26 Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding Unknown status NCT00567216 Phase 4 Nadolol
27 The Effect of Anticoagulation in Cirrhotic Patients With Portal Vein Thrombosis:A Multicenter RCT Unknown status NCT02630095 Phase 4 Nadroparin Calcium and Warfarin
28 The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Unknown status NCT02398357 Phase 4 Nadroparin Calcium and Warfarin
29 Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP) Unknown status NCT00761098 Phase 4 Standard Care;Experimental
30 Primary Prevention of Gastric Variceal Bleeding : Endoscopic Treatment Versus Non-selective Beta-blocker Unknown status NCT01298271 Phase 4 propranolol
31 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
32 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
33 Propofol and Fentanyl Versus Midazolam and Fentanyl for Endoscopy Sedation in Cirrhotic Patients Unknown status NCT00906139 Phase 4 Propofol;Midazolam;Fentanyl
34 Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
35 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4 lamivudine;Telbivudine;Enticavir;Adefovir Dipivoxil Tablets
36 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
37 Treatment for Prevention of Variceal Rebleeding Guided by the Hemodynamic Response Unknown status NCT00563602 Phase 4
38 The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites Unknown status NCT02755701 Phase 4 Branched-chain Amino Acid;Placebo
39 Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response Unknown status NCT01530711 Phase 4 Terlipressin and albumin
40 Transfusion Requirements in Gastrointestinal (GI) Bleeding Unknown status NCT00414713 Phase 4
41 A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Unknown status NCT01965418 Phase 4 Fufang Biejia Ruangan Tablet;Placebo
42 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
43 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
44 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
45 EFFORT Further Extension Study Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
46 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication Unknown status NCT01894269 Phase 4 Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
47 The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure Unknown status NCT02489864 Phase 4 Terlipressin
48 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
49 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
50 Multidisciplinary Approach Versus Conventional Approach in Colonic Preparation of Hospitalized Patients Unknown status NCT01853709 Phase 4 Polyethylene glycol (PEG);Bisacodyl

Search NIH Clinical Center for Liver Cirrhosis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Cirrhosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Liver Cirrhosis:
Autologous bone marrow-derived mesenchymal stem cells for liver cirhosis
Autologous bone marrow-derived stem cells for treatment of liver cirrhosis
Autologous hematopoietic stem cells for treatment of end-stage chronic liver disease
Bone marrow-derived endothelial progenitor cells for advanced liver cirrhosis
Bone marrow-derived mesenchymal stem cells for treatment of cirrhosis-related refractory ascites
Bone marrow-derived mesenchymal stem cells for treatment of liver cirrhosis
Hepatocyte transplantation for treatment of liver failure and inherited metabolic diseases
Mesenchymal stem cells for liver cirrhosis
NU215-01, human umbilical cord mesenchymal stem cells for treatment of liver cirrhosis
Peripheral blood-derived CD34+ or mononuclear cells for liver cirrhosis
StempeucelLC�, mesenchymal stem cells for liver cirrhosis
Umbilical cord-derived mesenchymal stem cells for treatment of liver cirrhosis
Embryonic/Adult Cultured Cells Related to Liver Cirrhosis:
Bone marrow-derived mesenchymal stem cells (family) PMIDs: 21771778 22121493
Peripheral blood-derived hematopoietic stem cells PMIDs: 20587151
Bone marrow-derived endothelial progenitor cells (family)
Hepatocytes
Umbilical cord-derived mesenchymal stem cells
Peripheral blood-derived hematopoietic stem cells (family)
Peripheral blood-derived mesenchymal stem cells (family)
Bone marrow-derived mesenchymal stem cells (Stempeucel�) PMIDs: 18720444
Umbilical cord-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: liver cirrhosis

Genetic Tests for Liver Cirrhosis

Genetic tests related to Liver Cirrhosis:

# Genetic test Affiliating Genes
1 Liver Cirrhosis 30

Anatomical Context for Liver Cirrhosis

MalaCards organs/tissues related to Liver Cirrhosis:

42
Liver, Bone, Testes, Kidney, Bone Marrow, Spleen, Endothelial
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Liver Cirrhosis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
3 Liver Sinusoids Hepatic Stellate Cells Affected by disease
4 Liver Liver Lobule Hepatocytes Affected by disease
5 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
6 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Liver Cirrhosis

Articles related to Liver Cirrhosis:

(show top 50) (show all 5630)
# Title Authors Year
1
Opportunities to Prevent Alcoholic Liver Cirrhosis in High-Risk Populations: A Systematic Review With Meta-Analysis. ( 30353053 )
2019
2
Anticoagulation for Atrial Fibrillation in Cirrhosis of the Liver: Are Low-Dose Non-Vitamin K Oral Anticoagulants a Reasonable Alternative to Warfarin? ( 30834801 )
2019
3
Late onset cardiac cirrhosis and portal hypertensive ascites after atrial fibrillation ablation. ( 30419795 )
2019
4
Focal Nodular Hyperplasia Mimicked Hepatocellular Carcinoma in an Autoimmune Hepatitis Patient With Regression of Cirrhosis. ( 30845888 )
2019
5
Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis. ( 30912093 )
2019
6
Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. ( 30889843 )
2019
7
Comment on: Expressions of MiR-132 in patients with chronic hepatitis B, posthepatitic cirrhosis and hepatitis B virus-related hepatocellular carcinoma. ( 30840257 )
2019
8
Protective effects of coffee consumption following liver transplantation for hepatocellular carcinoma in cirrhosis. ( 30811647 )
2019
9
Preoperative Prognosticators of Safe Laparoscopic Hepatocellular Carcinoma Resection in Advanced Cirrhosis: a Propensity Score Matching Population-Based Analysis of 1799 Western Patients. ( 30820798 )
2019
10
Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. ( 30829446 )
2019
11
The Changing Face of Hepatocellular Carcinoma: Forecasting Prevalence of Nonalcoholic Steatohepatitis and Hepatitis C Cirrhosis. ( 30765939 )
2019
12
A targeted and multifunctional technology for identification between hepatocellular carcinoma and liver cirrhosis. ( 30776888 )
2019
13
Histologic severity of liver cirrhosis: A key factor affecting surgical outcomes of hepatocellular carcinoma in patients with portal hypertension. ( 30782497 )
2019
14
Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma. ( 30788118 )
2019
15
Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment. ( 30791221 )
2019
16
Efficacy and Safety of Microwave Ablation (MWA) for Hepatocellular Carcinoma (HCC) in Difficult Anatomical Sites in Egyptian Patients with Liver Cirrhosis ( 30678453 )
2019
17
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules. ( 30684506 )
2019
18
Hepatocellular Carcinoma versus Other Hepatic Malignancy in Cirrhosis: Performance of LI-RADS Version 2018. ( 30694166 )
2019
19
Laparoscopic Versus Open Hepatectomy in Short- and Long-Term Outcomes of the Hepatocellular Carcinoma Patients with Cirrhosis: A Systematic Review and Meta-Analysis. ( 30702362 )
2019
20
Hepatitis D virus infection, cirrhosis, and hepatocellular carcinoma in The Gambia. ( 30661282 )
2019
21
Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. ( 30367397 )
2019
22
Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy. ( 30339294 )
2019
23
Complete Heart Block due to Octreotide Infusion in Patient with Cryptogenic Cirrhosis. ( 30911266 )
2019
24
Hip fracture risk in patients with cirrhosis: does diabetes mellitus matter? ( 30761561 )
2019
25
Hip fracture risk in patients with cirrhosis: does diabetes mellitus matter? ( 30762889 )
2019
26
Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan: a propensity score-matching analysis. ( 30779213 )
2019
27
Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With Cirrhosis. ( 30848730 )
2019
28
Decreased Mean Kurtosis in the Putamen is a Diagnostic Feature of Minimal Hepatic Encephalopathy in Patients with Cirrhosis. ( 30626839 )
2019
29
Predicting Overt Hepatic Encephalopathy for the Population with Cirrhosis. ( 30703852 )
2019
30
Associated vitamin D deficiency is a risk factor for the complication of HCV-related liver cirrhosis including hepatic encephalopathy and spontaneous bacterial peritonitis. ( 30706253 )
2019
31
Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues. ( 30706419 )
2019
32
L-Ornithine L-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Novel Insights and Translation to the Clinic. ( 30706421 )
2019
33
Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology. ( 30706423 )
2019
34
L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses. ( 30706425 )
2019
35
Successful definitive concurrent chemoradiotherapy in a patient with esophageal cancer and Child-Pugh B cirrhosis of the liver. ( 30880788 )
2019
36
Can we perform esophagectomy for esophageal cancer patients with concomitant liver cirrhosis? A comprehensive systematic review and meta-analysis. ( 30828736 )
2019
37
Transient Elastography and Ultrasonography: Optimal Evaluation of Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Concurrent with Nonalcoholic Fatty Liver Disease. ( 30809540 )
2019
38
Statins and Abnormal Liver Enzymes. ( 30855731 )
2019
39
Impact of Helicobacter pylori Infection on Gastric Variceal Bleeding among Patients with Liver Cirrhosis. ( 30881448 )
2019
40
Progressive hepatic cirrhosis early after allogeneic hematopoietic stem cell transplantation in a patient with chronic hepatitis C infection ( 30717587 )
2019
41
Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. ( 30868245 )
2019
42
Circulating levels of CXCL11 and CXCL12 are biomarkers of cirrhosis in patients with chronic hepatitis C infection. ( 30826602 )
2019
43
Previous hepatitis E virus infection, cirrhosis and insulin resistance in patients with chronic hepatitis C. ( 30836071 )
2019
44
Alcohol-associated liver disease, not hepatitis B, is the major cause of cirrhosis in Asia. ( 30782425 )
2019
45
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. ( 30793345 )
2019
46
Reply to: "Alcohol-associated liver disease, not hepatitis B, is the major cause of cirrhosis in Asia". ( 30795934 )
2019
47
Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers. ( 30807443 )
2019
48
Albumin-Bilirubin (ALBI) as an accurate and simple prognostic score for chronic hepatitis B-related liver cirrhosis. ( 30765220 )
2019
49
Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis. ( 30765933 )
2019
50
Spleen-Associated Effects on Immunity in Hepatitis B Virus-Related Cirrhosis with Portal Hypertension. ( 30676849 )
2019

Variations for Liver Cirrhosis

ClinVar genetic disease variations for Liver Cirrhosis:

6 (show all 16)
# Gene Variation Type Significance SNP ID Assembly Location
1 KRT18 NM_000224.2(KRT18): c.383A> T (p.His128Leu) single nucleotide variant Pathogenic,risk factor rs57758506 GRCh37 Chromosome 12, 53343340: 53343340
2 KRT18 NM_000224.2(KRT18): c.383A> T (p.His128Leu) single nucleotide variant Pathogenic,risk factor rs57758506 GRCh38 Chromosome 12, 52949556: 52949556
3 KRT8 NM_002273.3(KRT8): c.184G> T (p.Gly62Cys) single nucleotide variant Pathogenic,risk factor rs11554495 GRCh37 Chromosome 12, 53298582: 53298582
4 KRT8 NM_002273.3(KRT8): c.184G> T (p.Gly62Cys) single nucleotide variant Pathogenic,risk factor rs11554495 GRCh38 Chromosome 12, 52904798: 52904798
5 KRT8 NM_002273.3(KRT8): c.160T> C (p.Tyr54His) single nucleotide variant Pathogenic rs57749775 GRCh37 Chromosome 12, 53298606: 53298606
6 KRT8 NM_002273.3(KRT8): c.160T> C (p.Tyr54His) single nucleotide variant Pathogenic rs57749775 GRCh38 Chromosome 12, 52904822: 52904822
7 FARSB NM_005687.4(FARSB): c.1381A> C (p.Thr461Pro) single nucleotide variant Pathogenic rs1396171148 GRCh38 Chromosome 2, 222613892: 222613892
8 FARSB NM_005687.4(FARSB): c.1381A> C (p.Thr461Pro) single nucleotide variant Pathogenic rs1396171148 GRCh37 Chromosome 2, 223478611: 223478611
9 FARSB NM_005687.4(FARSB): c.784A> G (p.Lys262Glu) single nucleotide variant Pathogenic rs1553554543 GRCh37 Chromosome 2, 223496325: 223496325
10 FARSB NM_005687.4(FARSB): c.784A> G (p.Lys262Glu) single nucleotide variant Pathogenic rs1553554543 GRCh38 Chromosome 2, 222631606: 222631606
11 FARSB NM_005687.4(FARSB): c.1202G> A (p.Arg401Gln) single nucleotide variant Pathogenic rs1553553086 GRCh37 Chromosome 2, 223488418: 223488418
12 FARSB NM_005687.4(FARSB): c.1202G> A (p.Arg401Gln) single nucleotide variant Pathogenic rs1553553086 GRCh38 Chromosome 2, 222623699: 222623699
13 FARSB NM_005687.4(FARSB): c.755T> C (p.Phe252Ser) single nucleotide variant Pathogenic rs1466642025 GRCh38 Chromosome 2, 222631635: 222631635
14 FARSB NM_005687.4(FARSB): c.755T> C (p.Phe252Ser) single nucleotide variant Pathogenic rs1466642025 GRCh37 Chromosome 2, 223496354: 223496354
15 FARSB NM_005687.4(FARSB): c.226T> C (p.Cys76Arg) single nucleotide variant Pathogenic rs1419129874 GRCh38 Chromosome 2, 222642894: 222642894
16 FARSB NM_005687.4(FARSB): c.226T> C (p.Cys76Arg) single nucleotide variant Pathogenic rs1419129874 GRCh37 Chromosome 2, 223507613: 223507613

Copy number variations for Liver Cirrhosis from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 210504 6 30400000 36600000 Copy number C4B Liver cirrhosis

Expression for Liver Cirrhosis

Search GEO for disease gene expression data for Liver Cirrhosis.

Pathways for Liver Cirrhosis

Pathways related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Sup